Evidence map›Paper›PMID 39989290›Full record

ArticleEuropean journal of immunology2025

BTK-Inhibition Enhances TLR-7-Mediated Interferon-Alpha Production in pDCs by Blocking the Inhibitory BDCA-2 Pathway.

Laura Ceglarek, Ramona Gerhards, Vinicius Boldrini, Christian Wichmann, Anneli Peters, Edgar Meinl

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Laura CeglarekInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.ORCID 0009-0005-7117-0335
Ramona GerhardsInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Vinicius BoldriniInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Christian WichmannDepartment of Transfusion Medicine, Cell Therapeutics and Hemostaseology, University Hospital, LMU Munich, Munich, Germany.
Anneli PetersInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Edgar MeinlInstitute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.ORCID 0000-0002-2570-6785

Funding

CAPES/Alexander von Humboldt (AvH)-Stiftung : Call 19/2022 (research fellowhip to VB)Deutsche Forschungsgemeinschaft SFB TR128
6 · The paper itself

Abstract

In pDCs, BTK-inhibition (BTKi) blocks the IFN-α production via TLR-9, but not via TLR-7. Upon TLR-7 stimulation, BTKi enhances the production of IFN-α by blocking the inhibitory BDCA-2 pathway. This might explain partially the failure of BTKi in SLE and is of interest for BTKi trials in multiple sclerosis.

Indexed as

Agammaglobulinaemia Tyrosine KinaseDendritic CellsInterferon-alphaToll-Like Receptor 7AnimalsHumansLupus Erythematosus, SystemicSignal TransductionToll-Like Receptor 9Agammaglobulinaemia Tyrosine KinaseBTK protein, humanInterferon-alphaTLR7 protein, humanToll-Like Receptor 7Toll-Like Receptor 9BTK‐imultiple sclerosispDCssystemic lupus erythematosusTLR signaling

Identifiers

PMID39989290
PMCPMC11848701

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.